Simeon George - Net Worth and Insider Trading

Simeon George Net Worth

The estimated net worth of Simeon George is at least $647 Million dollars as of 2024-12-28. Simeon George is the Director of Principia Biopharma Inc and owns about 2,982,855 shares of Principia Biopharma Inc (PRNB) stock worth over $298 Million. Simeon George is the Director of Turning Point Therapeutics Inc and owns about 2,253,660 shares of Turning Point Therapeutics Inc (TPTX) stock worth over $171 Million. Simeon George is also the Director of CRISPR Therapeutics AG and owns about 3,220,627 shares of CRISPR Therapeutics AG (CRSP) stock worth over $129 Million. Besides these, Simeon George also holds Design Therapeutics Inc (DSGN) , Nkarta Inc (NKTX) . Details can be seen in Simeon George's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Simeon George has not made any transactions after 2024-03-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Simeon George

Simeon George Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Simeon George owns 10 companies in total, including Principia Biopharma Inc (PRNB) , Nkarta Inc (NKTX) , and Turning Point Therapeutics Inc (TPTX) among others .

Click here to see the complete history of Simeon George’s form 4 insider trades.

Insider Ownership Summary of Simeon George

Ticker	Comapny	Transaction Date	Type of Owner
PRNB	Principia Biopharma Inc	2020-09-28	director
NKTX	Nkarta Inc	2024-03-27	director
TPTX	Turning Point Therapeutics Inc	2020-05-21	director
		2016-10-24	director
		2015-05-05	director
		2014-02-04	director
		2022-02-03	10 percent owner
		2022-12-20	director & 10 percent owner
		2021-08-25	10 percent owner
		2014-02-04	director

Simeon George Latest Holdings Summary

Simeon George currently owns a total of 5 stocks. Among these stocks, Simeon George owns 2,982,855 shares of Principia Biopharma Inc (PRNB) as of October 18, 2019, with a value of $298 Million and a weighting of 46.09%. Simeon George owns 2,253,660 shares of Turning Point Therapeutics Inc (TPTX) as of May 21, 2020, with a value of $171 Million and a weighting of 26.46%. Simeon George also owns 3,220,627 shares of CRISPR Therapeutics AG (CRSP) as of October 24, 2016, with a value of $129 Million and a weighting of 19.91%. The other 2 stocks Design Therapeutics Inc (DSGN) , Nkarta Inc (NKTX) have a combined weighting of 7.54% among all his current holdings.

Latest Holdings of Simeon George

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PRNB	Principia Biopharma Inc	2019-10-18	2,982,855	100.05	298,434,643
TPTX	Turning Point Therapeutics Inc	2020-05-21	2,253,660	76.01	171,300,697
CRSP	CRISPR Therapeutics AG	2016-10-24	3,220,627	40.02	128,889,493
DSGN	Design Therapeutics Inc	2022-12-20	6,526,476	6.25	40,790,475
NKTX	Nkarta Inc	2024-03-27	3,333,333	2.41	8,033,333

Holding Weightings of Simeon George

Simeon George Form 4 Trading Tracker

According to the SEC Form 4 filings, Simeon George has made a total of 0 transactions in Principia Biopharma Inc (PRNB) over the past 5 years. The most-recent trade in Principia Biopharma Inc is the acquisition of 357,142 shares on October 18, 2019, which cost Simeon George around $10 Million.

According to the SEC Form 4 filings, Simeon George has made a total of 1 transactions in Turning Point Therapeutics Inc (TPTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Turning Point Therapeutics Inc is the acquisition of 83,333 shares on May 21, 2020, which cost Simeon George around $5 Million.

According to the SEC Form 4 filings, Simeon George has made a total of 0 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years. The most-recent trade in CRISPR Therapeutics AG is the acquisition of 66,500 shares on October 24, 2016, which cost Simeon George around $931,000.

More details on Simeon George's insider transactions can be found in the Insider Trading History of Simeon George table.

Insider Trading History of Simeon George

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Simeon George Trading Performance

GuruFocus tracks the stock performance after each of Simeon George's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Simeon George is 10.46%. GuruFocus also compares Simeon George's trading performance to market benchmark return within the same time period. The performance of stocks bought by Simeon George within 3 months outperforms 6 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Simeon George's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Simeon George

Average Return

Average return per transaction

Outperforming Transactions

5 out of 8 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-1.18
Relative Return to S&P 500(%)	-1.97

Simeon George Ownership Network

Ownership Network List of Simeon George

No Data

Ownership Network Relation of Simeon George

Simeon George Owned Company Details

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Simeon George is the director of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Principia Biopharma Inc Insider Transactions

No Available Data

What does Nkarta Inc do?

Who are the key executives at Nkarta Inc?

Simeon George is the director of Nkarta Inc. Other key executives at Nkarta Inc include Chief Legal Officer Alicia J. Hager , Chief Medical Officer David Shook , and Sr. VP & Technical Operations Ralph Brandenberger .

Nkarta Inc (NKTX) Insider Trades Summary

Over the past 18 months, Simeon George made 1 insider transaction in Nkarta Inc (NKTX) with a net purchase of 2,000,000. Other recent insider transactions involving Nkarta Inc (NKTX) include a net sale of 9,159 shares made by James Trager , a net sale of 8,677 shares made by Alicia J. Hager , and a net sale of 5,339 shares made by David Shook .

In summary, during the past 3 months, insiders sold 0 shares of Nkarta Inc (NKTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 37,383 shares of Nkarta Inc (NKTX) were sold and 5,000,000 shares were bought by its insiders, resulting in a net purchase of 4,962,617 shares.

Nkarta Inc (NKTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nkarta Inc Insider Transactions

No Available Data

What does Turning Point Therapeutics Inc do?

Who are the key executives at Turning Point Therapeutics Inc?

Simeon George is the director of Turning Point Therapeutics Inc. Other key executives at Turning Point Therapeutics Inc include EVP & Chief Financial Officer Paolo Tombesi , SVP & Chief Commercial Officer Steve M Sabus , and SVP & General Counsel Brian Sun .

Turning Point Therapeutics Inc (TPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Turning Point Therapeutics Inc (TPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Turning Point Therapeutics Inc (TPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Turning Point Therapeutics Inc (TPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Turning Point Therapeutics Inc Insider Transactions

No Available Data

What does CRISPR Therapeutics AG do?

Who are the key executives at CRISPR Therapeutics AG?

Simeon George is the director of CRISPR Therapeutics AG. Other key executives at CRISPR Therapeutics AG include Chief Business Officer Samarth Kulkarni , General Counsel and Secretary James R. Kasinger , and Chief Financial Officer Raju Prasad .

CRISPR Therapeutics AG (CRSP) Insider Trades Summary

Over the past 18 months, Simeon George made no insider transaction in CRISPR Therapeutics AG (CRSP). Other recent insider transactions involving CRISPR Therapeutics AG (CRSP) include a net sale of 199,630 shares made by Samarth Kulkarni , a net sale of 6,949 shares made by James R. Kasinger , and a net sale of 3,524 shares made by Raju Prasad .

In summary, during the past 3 months, insiders sold 50,382 shares of CRISPR Therapeutics AG (CRSP) in total and bought 0 shares, with a net sale of 50,382 shares. During the past 18 months, 213,469 shares of CRISPR Therapeutics AG (CRSP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 213,469 shares.

CRISPR Therapeutics AG (CRSP)'s detailed insider trading history can be found in Insider Trading Tracker table.

CRISPR Therapeutics AG Insider Transactions

No Available Data

What does HTG Molecular Diagnostics Inc do?

Who are the key executives at HTG Molecular Diagnostics Inc?

Simeon George is the director of HTG Molecular Diagnostics Inc. Other key executives at HTG Molecular Diagnostics Inc include Senior VP of Therapeutics Stephen Barat , 10 percent owner L5 Capital Inc. , and SVP/Chief Commercial Officer Byron Lawson .

HTG Molecular Diagnostics Inc (HTGMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of HTG Molecular Diagnostics Inc (HTGMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of HTG Molecular Diagnostics Inc (HTGMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

HTG Molecular Diagnostics Inc (HTGMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

HTG Molecular Diagnostics Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Simeon George is the director of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , director & President and CEO William D Clark , and CHIEF FINANCIAL OFFICER Diantha Duvall .

Genocea Biosciences Inc (GNCAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GNCAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GNCAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GNCAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

What does Arcellx Inc do?

Who are the key executives at Arcellx Inc?

Simeon George is the 10 percent owner of Arcellx Inc. Other key executives at Arcellx Inc include Chief Financial Officer Michelle Gilson , Chief Medical Officer Christopher Heery , and director & See Remarks Rami Elghandour .

Arcellx Inc (ACLX) Insider Trades Summary

Over the past 18 months, Simeon George made no insider transaction in Arcellx Inc (ACLX). Other recent insider transactions involving Arcellx Inc (ACLX) include a net sale of 343,050 shares made by Christopher Heery , a net sale of 80,979 shares made by Kavita Patel , and a net sale of 69,452 shares made by Michelle Gilson .

In summary, during the past 3 months, insiders sold 79,094 shares of Arcellx Inc (ACLX) in total and bought 0 shares, with a net sale of 79,094 shares. During the past 18 months, 1,610,633 shares of Arcellx Inc (ACLX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,610,633 shares.

Arcellx Inc (ACLX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arcellx Inc Insider Transactions

No Available Data

What does Design Therapeutics Inc do?

Who are the key executives at Design Therapeutics Inc?

Simeon George is the director & 10 percent owner of Design Therapeutics Inc. Other key executives at Design Therapeutics Inc include director & President and CEO Joao Md Siffert , 10 percent owner Sr One Capital Fund I Aggregator Lp , and director & 10 percent owner Stella Xu .

Design Therapeutics Inc (DSGN) Insider Trades Summary

Over the past 18 months, Simeon George made no insider transaction in Design Therapeutics Inc (DSGN). Other recent insider transactions involving Design Therapeutics Inc (DSGN) include a net purchase of 1,420,126 shares made by Arsani William , a net purchase of 8,194 shares made by Deepa Prasad , and a net purchase of 26,965 shares made by John P. Schmid .

In summary, during the past 3 months, insiders sold 3,806 shares of Design Therapeutics Inc (DSGN) in total and bought 0 shares, with a net sale of 3,806 shares. During the past 18 months, 818,680 shares of Design Therapeutics Inc (DSGN) were sold and 2,296,265 shares were bought by its insiders, resulting in a net purchase of 1,477,585 shares.

Design Therapeutics Inc (DSGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Design Therapeutics Inc Insider Transactions

No Available Data

What does eFFECTOR Therapeutics Inc do?

Who are the key executives at eFFECTOR Therapeutics Inc?

Simeon George is the 10 percent owner of eFFECTOR Therapeutics Inc. Other key executives at eFFECTOR Therapeutics Inc include 10 percent owner Sr One Capital Fund I Aggregator Lp , director & 10 percent owner & Chief Executive Officer Christopher B Ehrlich , and Chief Business Officer Mayank Gandhi .

eFFECTOR Therapeutics Inc (EFTR) Insider Trades Summary

Over the past 18 months, Simeon George made no insider transaction in eFFECTOR Therapeutics Inc (EFTR). Other recent insider transactions involving eFFECTOR Therapeutics Inc (EFTR) include a net sale of 609,163 shares made by Sr One Capital Fund I Aggregator Lp ,

In summary, during the past 3 months, insiders sold 0 shares of eFFECTOR Therapeutics Inc (EFTR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 24,367 shares of eFFECTOR Therapeutics Inc (EFTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 24,367 shares.

eFFECTOR Therapeutics Inc (EFTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

eFFECTOR Therapeutics Inc Insider Transactions

No Available Data

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Simeon George is the director of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , EVP PHARM SCI & MFG Stapleton Raymond D Jr , and 10 percent owner Paul Edward Walker .

Genocea Biosciences Inc (GGNNQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GGNNQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GGNNQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GGNNQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genocea Biosciences Inc Insider Transactions

No Available Data

Simeon George Mailing Address

Above is the net worth, insider trading, and ownership report for Simeon George. You might contact Simeon George via mailing address: 161 Washington Street, Suite 500, Conshohocken Pa 19428.

Discussions on Simeon George

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.